The KCNJ2 Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population of HeLa cells with targeted disruption of the KCNJ2 gene. This loss-of-function model enables studies of the inward rectifier potassium channel Kir2.1, encoded by KCNJ2, in a human cancer cell background. The polyclonal format provides a diverse array of editing events, suitable for applications where a mixed knockout population is advantageous.
HeLa cells are an immortalized cervical epithelial adenocarcinoma line containing integrated HPV-18 sequences, characterized by rapid proliferation and genomic instability. They serve as a foundational model in biomedical research for cancer biology, signal transduction, and pharmacological testing. This well-established background offers a reproducible system to assess the impact of KCNJ2 disruption on cellular excitability and ion channel-dependent processes.
The KCNJ2 gene product, Kir2.1, is an inward rectifier potassium channel that mediates the IK1 current, which stabilizes resting membrane potential and controls excitability. Kir2.1 is regulated by membrane depolarization, PIP2, PKA, PKC, and magnesium ions. It interacts with scaffolding proteins SAP97, DLG1, CASK, and Lin7, which govern its trafficking and functional integration. Downstream, Kir2.1-driven potassium flux modulates membrane potential, thereby influencing voltage-gated signaling cascades. Other subfamily members include KCNJ12 (Kir2.2), KCNJ4 (Kir2.3), and KCNJ14 (Kir2.4).
Disruption of KCNJ2 in HeLa cells permits dissection of Kir2.1-dependent roles in membrane potential regulation within a cancer context, where ion channel activity may impact proliferation, migration, or apoptosis. Although the endogenous expression level of KCNJ2 in HeLa cells is not fully characterized, knockout can uncover contributions to cellular homeostasis. This model is also valuable for exploring channelopathy-related mechanisms, given the association of KCNJ2 mutations with Andersen-Tawil syndrome, short QT syndrome type 3, and familial atrial fibrillation.
Applications include investigating ion channel function in cancer, screening drugs that modulate potassium channels, and studying membrane potential-dependent signaling. Typical analyses involve western blotting for Kir2.1 protein, quantitative RT-PCR for KCNJ2 mRNA, patch-clamp electrophysiology for IK1 currents, and immunofluorescence for channel localization. Researchers can leverage this model to identify Kir2.1 interaction partners or evaluate therapeutic compounds. For technical inquiries, please contact Ascent Research.
